AAAAAA

   
Results: 1-7 |
Results: 7
Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events
Authors: Tamminga, WJ Wemer, J Oosterhuis, B Wieling, J Touw, DJ de Zeeuw, RA de Leij, LFMH Jonkman, JHG
Citation: Wj. Tamminga et al., Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events, BR J CL PH, 51(5), 2001, pp. 471-474
Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge
Authors: Stangier, J Su, CAPF van Heiningen, PNM Meinicke, T van Lier, JJ de Bruin, H Tamminga, WJ Jonkman, JHG
Citation: J. Stangier et al., Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge, J CARDIO PH, 38(5), 2001, pp. 672-685
An optimized methodology for combined phenotyping and genotyping on CYP2D6and CYP2C19
Authors: Tamminga, WJ Wemer, J Oosterhuis, B Brakenhoff, JPG Gerrits, MGF de Zeeuw, RA de Leij, LFMH Jonkman, JHG
Citation: Wj. Tamminga et al., An optimized methodology for combined phenotyping and genotyping on CYP2D6and CYP2C19, EUR J CL PH, 57(2), 2001, pp. 143-146
Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening
Authors: Wieling, J Tamminga, WJ Sakiman, EP Oosterhuis, B Wemer, J Jonkman, JHG
Citation: J. Wieling et al., Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening, THER DRUG M, 22(4), 2000, pp. 486-496
Absorption, metabolism, and excretion of intravenously and orally administered [C-14]telmisartan in healthy volunteers
Authors: Stangier, J Schmidt, J Turck, D Switek, H Verhagen, A Peeters, PAM van Marle, SP Tamminga, WJ Sollie, FAE Jonkman, JHG
Citation: J. Stangier et al., Absorption, metabolism, and excretion of intravenously and orally administered [C-14]telmisartan in healthy volunteers, J CLIN PHAR, 40(12), 2000, pp. 1312-1322
Clopidogrel, a novel antiplatelet agent, and digoxin: Absence of pharmacodynamic and pharmacokinetic interaction
Authors: Peeters, PAM Crijns, HJMJ Tamminga, WJ Jonkman, JHG Dickinson, JP Necciari, J
Citation: Pam. Peeters et al., Clopidogrel, a novel antiplatelet agent, and digoxin: Absence of pharmacodynamic and pharmacokinetic interaction, SEM THROMB, 25, 1999, pp. 51-54
CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences
Authors: Tamminga, WJ Wemer, J Oosterhuis, B Wieling, J Wilffert, B de Leij, LFMH de Zeeuw, RA Jonkman, JHG
Citation: Wj. Tamminga et al., CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences, EUR J CL PH, 55(3), 1999, pp. 177-184
Risultati: 1-7 |